Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny dose of LSD help adults with ADHD?

NCT ID NCT05200936

Disease control Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether repeated low doses of LSD (called MM120) can safely help adults with ADHD. Fifty-three adults took either the drug or a placebo, and researchers measured changes in ADHD symptoms using a standard rating scale. The goal was to see if this approach could be a new way to manage ADHD without needing daily medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LSD (lysergic acid diethylamide) as a low-dose tartrate salt (MM120)
What this could lead to
If it works, this could point toward a new, non-daily medication option for managing ADHD symptoms in adults.
What could go wrong
This is a small, early-phase proof-of-concept trial with only 53 participants. The psychedelic effects of LSD may cause hallucinations or other side effects, and it is not yet proven effective or safe for ADHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

53 people

The number who actually took part.

Started

Dec 2021

Finished

Dec 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female outpatients ≥ 18 and ≤ 65 years of age at Screening * Patients with the diagnosis of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) ADHD, as determined by clinical evaluation and confirmed by structured interview (MINI). * Adequate organ function. * Able to understand the study procedures and understand risks associated with the study, and sign written informed consent to participate in the study. * Must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete. Exclusion Criteria: * Past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder. * Past or present bipolar disorder (DSM-5). * Any lifetime history of suicide attempt. * Once Informed Consent form is signed, not willing or able to stop any prescription or non-prescription ADHD medications. * Use of investigational medication/treatment in the past 30 days. * Patients with a positive urine drug screen with the exception of THC or its metabolites. * Pregnant or nursing females.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD Attention deficit disorder

Contacts and locations

Locations

  • Maastricht University

    Maastricht, Netherlands

  • University Hospital Basel

    Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.